You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Moodys
Medtronic
Express Scripts

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

HETLIOZ Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Hetlioz patents expire, and when can generic versions of Hetlioz launch?

Hetlioz is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are eleven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and twenty-eight patent family members in thirty-one countries.

The generic ingredient in HETLIOZ is tasimelteon. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tasimelteon profile page.

US ANDA Litigation and Generic Entry Outlook for Hetlioz

Hetlioz was eligible for patent challenges on January 31, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 12, 2035. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for HETLIOZ
Drug Prices for HETLIOZ

See drug prices for HETLIOZ

Generic Entry Opportunity Date for HETLIOZ
Generic Entry Date for HETLIOZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for HETLIOZ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanda PharmaceuticalsPhase 1
Vanda PharmaceuticalsPhase 4

See all HETLIOZ clinical trials

Recent Litigation for HETLIOZ

Identify potential future generic entrants

District Court Litigation
Case NameDate
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.2020-01-22
Vanda Pharmaceuticals Inc. v. Apotex Inc.2020-01-21
Vanda Pharmaceuticals Inc. v. Apotex Inc.2019-12-30

See all HETLIOZ litigation

Pharmacology for HETLIOZ
Synonyms for HETLIOZ
(-)-(trans)-N-[[2-(2,3-Dihydrobenzofuran-4-yl)cycloprop-1-yl] methyl]propanamide
(trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl) cyclopropyl]methyl]propanamide
(trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide
609799-22-6
799T226
AC-6143
ACT06729
AK188029
AKOS025149360
AS-35291
BCP07180
BMS 214778
BMS-214,778
BMS-214778
CHEBI:79042
CHEMBL2103822
CS-5512
D09388
DB09071
DTXSID70209826
EX-A2729
GTPL7393
Hetlioz (TN)
HY-14803
J3.640.465E
KS-0000063S
N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide
N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide
N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide
N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
Propanamide, N-(((1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)-
PTOIAAWZLUQTIO-GXFFZTMASA-N
Q7687250
s4281
SB16782
SCHEMBL3505912
SHS4PU80D9
Tasimelteon
Tasimelteon (USAN/INN)
Tasimelteon [USAN:INN]
Tasimelteon, >=98% (HPLC)
tasimelteonum
UNII-SHS4PU80D9
VEC 162
VEC-162
X5820
ZINC4392649
Paragraph IV (Patent) Challenges for HETLIOZ
Tradename Dosage Ingredient NDA Submissiondate
HETLIOZ CAPSULE;ORAL tasimelteon 205677 2018-01-31

US Patents and Regulatory Information for HETLIOZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Moodys
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.